Innate Pharma S.A. (IPHA.Q) announced today that AstraZeneca has presented results from the randomized COAST Phase 2 trial during the European Society for Medical Oncology (ESMO) Congress 2021 on…
cancer treatment
Leap Therapeutics (LPTX.Q) announced today that it will be presenting initial data from the first-line cohort of the DisTinGuish study at the European Society for Medical Oncology (ESMO) Congress….
Adaptimmune Therapeutics (ADAP.Q) announced today that it has entered into a strategic collaboration and license agreement with Genentech, a member of the Roche Group, to develop and commercialize allogenic…
Cancer is a bitch. Even if you haven’t had to battle against cancer yourself, you likely know someone who has. Unfortunately for me, that person was my mom; however,…
Trillium Therapeutics (TRIL.V) announced today that the Company has entered into a definitive agreement under which Pfizer Inc. will acquire Trillium. “We’re delighted to announce Pfizer’s proposed…
PharmaCyte Biotech (PMCB.Q) released a statement from Kenneth L. Waggoner, the Chief Executive Officer of PharmaCyte, on August 16, 2021. In this statement, Mr. Waggoner comments on the Company’s…
Spectrum Pharmaceuticals (SPPI.Q) announced today that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the Company’s Biologics License Application (BLA)…
ERYTECH Pharma (ERYP.Q) announced today that the U.S. Food and Drug Administration (FDA) has granted eryaspase Fast Track designation for the treatment of acute lymphocytic leukemia (ALL) patients who…
Tyme Technologies (TYME.Q) announced today that the United States Patent and Trademark Office has granted the Company additional patent claims related to the Company’s metabolomic technology platform. …
Aprea Therapeutics (APRE.Q) today announced positive results from its Phase 2 trial evaluating eprenetapopt with azacitidine for post-transplant maintenance therapy in patients with TP53 mutant MDS and AML. “The…